Page last updated: 2024-12-07

acea 1011

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ACEA 1011: a glycine site NMDA receptor antagonist; produces analgesia during the late phase of subcutaneous formalin injection in mice [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
GlycinegenusA non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter.[MeSH]FabaceaeThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]

Cross-References

ID SourceID
PubMed CID127872
CHEMBL ID140296
SCHEMBL ID2639004
SCHEMBL ID3032750
SCHEMBL ID20636784
MeSH IDM0220976

Synonyms (16)

Synonym
5-chloro-7-trifluoromethyl-1,4-dihydro-2,3-quinoxalinedione
5-chloro-1,4-dihydro-7-(trifluoromethyl)-2,3-quinoxalinedione
acea-1011
acea 1011
2,3-quinoxalinedione, 5-chloro-1,4-dihydro-7-(trifluoromethyl)-
CHEMBL140296
5-chloro-7-(trifluoromethyl)-1,4-dihydroquinoxaline-2,3-dione
153504-72-4
SCHEMBL2639004
SCHEMBL3032750
5-chloro-7-trifluoromethyl-1,4-dihydroquinoxaline-2,3-dione
DTXSID00165345
acea1011
SCHEMBL20636784
5-chloro-7-(trifluoromethyl)quinoxaline-2,3-diol
AKOS040745458

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Recently, halogenated derivatives of quinoxaline-2,3-dione have been synthesized that possess bioavailability when parenterally administered and minimal psychotomimetic properties."( In vivo models of cerebral ischemia: effects of parenterally administered NMDA receptor glycine site antagonists.
Keana, JF; Ludwig, P; Martin, H; McAllister, A; Warner, DS; Weber, E, 1995
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (11)

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glutamate receptor 1Rattus norvegicus (Norway rat)Kb3.70000.59003.33007.0000AID147418
Glutamate receptor 2Rattus norvegicus (Norway rat)Kb3.70000.59003.17337.0000AID147418
Glutamate receptor 3Rattus norvegicus (Norway rat)Kb3.70000.59003.17787.0000AID147418
Glutamate receptor 4Rattus norvegicus (Norway rat)Kb3.70000.59003.28567.0000AID147418
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)Kb0.52000.00592.09697.0000AID143296
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)Kb0.52000.00592.41137.0000AID143296
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)Kb0.52000.00592.41137.0000AID143296
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)Kb0.52000.00592.41137.0000AID143296
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)Kb0.52000.00592.41137.0000AID143296
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)Kb0.52000.00592.41137.0000AID143296
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)Kb0.52000.00592.41137.0000AID143296
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 1Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID147418Binding affinity against rat brain Non N-methyl-D-aspartate glutamate receptor glutamate site expressed in Xenopus oocyte1995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
Synthesis and structure-activity relationships of substituted 1,4-dihydroquinoxaline-2,3-diones: antagonists of N-methyl-D-aspartate (NMDA) receptor glycine sites and non-NMDA glutamate receptors.
AID234072Selectivity for glycine site1995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
Synthesis and structure-activity relationships of substituted 1,4-dihydroquinoxaline-2,3-diones: antagonists of N-methyl-D-aspartate (NMDA) receptor glycine sites and non-NMDA glutamate receptors.
AID143296Binding affinity towards rat brain NMDA receptor glycine site expressed in Xenopus oocyte1995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
Synthesis and structure-activity relationships of substituted 1,4-dihydroquinoxaline-2,3-diones: antagonists of N-methyl-D-aspartate (NMDA) receptor glycine sites and non-NMDA glutamate receptors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's10 (83.33)18.2507
2000's0 (0.00)29.6817
2010's2 (16.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.78

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.78 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.34 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.78)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]